The report, presented by the Alliance for Patient Access (AfPA) and titled “Biosimilars: Can They Break Through?” will include discussion on the policy issues surrounding biosimilars in the United States. Topics will include:
- Given pending FDA regulations, what are the obstacles in getting biosimilars to market?
- What are the concerns surrounding the labeling or prescriber information, and why is the issue of naming so hotly contested?
People
Related Insights
25 April 2024
On Trial
A Trial Lawyer’s Trial Lawyer: Paul Callan On Trial
In this episode of On Trial, host Christopher DeGennaro sits down with seasoned trial lawyer and CNN legal commentator Paul Callan, former deputy chief of the Brooklyn District Attorney’s Office, with 30 years’ experience as a trial lawyer.
25 April 2024
Health Care Law Today
New Favorable OIG Advisory Opinion Allows Patient Assistant Programs Funded by Drug Manufacturers
The Office of Inspector General recently issued a new favorable advisory opinion regarding patient assistance programs for 12 specific disease funds.
09 May 2024
Events
The FTC Noncompete Rule: Where Do We Go From Here?
On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) voted to finalize a rule abolishing the vast majority of employee noncompetes across the United States.